Technical Analysis for BLCO - Bausch + Lomb Corporation

Grade Last Price % Change Price Change
A 17.0 -3.46% -0.61
BLCO closed down 3.46 percent on Monday, May 16, 2022, on 20 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Gapped Up Strength 0.00%
Gapped Down Weakness -3.46%
Hot IPO Pullback Bullish Swing Setup -2.69%
New 52 Week Low Weakness -2.69%
Gapped Down Weakness -2.69%
New 52 Week Closing Low Bearish 2.72%
Hot IPO Pullback Bullish Swing Setup 2.72%
Inside Day Range Contraction 2.72%
Gapped Up Strength 2.72%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 10 hours ago
Fell Below Previous Day's Low about 10 hours ago
60 Minute Opening Range Breakdown about 10 hours ago
Down 2 % about 10 hours ago
Down 1% about 12 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Bausch + Lomb Corporation Description

BLCO +11.11% Fri, May 6, 2022, 12:10 PM In this article: BLCO +11.11% Bausch + Lomb Begins Trading under "BLCO" on NYSE and TSX Fully Integrated Eye Health Business Sets Its Sights On Helping the World See Better To Live Better VAUGHAN, ON, May 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today launched as a publicly traded company focused on protecting and enhancing the gift of sight for millions of people around the world when it began trading under the "BLCO" symbol on the New York Stock Exchange and Toronto Stock Exchange.1 Experience the interactive Multichannel News Release here: "Today marks a tremendous milestone for Bausch + Lomb and an important step forward on the path to an independent company focused on eye health," said Joseph C. Papa, chairman and CEO, Bausch + Lomb. "Bausch + Lomb has long been associated with many of the most significant advances in eye health, and I am honored to work alongside our 12,000 global employees as we continue to focus on achieving our ongoing mission of helping people see better to live better all over the world." As a fully integrated eye health company, Bausch + Lomb offers a comprehensive portfolio of more than 400 products spanning contact lenses, lens and eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Since its founding in 1853, Bausch + Lomb has been dedicated to advancing eye health for people all over the world, and has pioneered hundreds of innovations, including SofLens®, the first mass-produced soft contact lens. Bausch + Lomb's current portfolio includes market-leading products, such as Biotrue® and renu® multi-purpose solutions, Biotrue® ONEday daily disposable contact lenses, LUMIFY® redness reliever eye drops, PreserVision® AREDS 2 formula eye vitamin and mineral supplements and VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%. Innovative Pipeline Expected to Drive Future Growth "Over the course of our company's nearly two century long history, Bausch + Lomb has always stood at the forefront of cutting-edge scientific and technological optical advancements, and today is no different. We are more focused than ever on developing and offering new treatments to meet unmet eye health needs," continued Mr. Papa. Bausch + Lomb currently has projects in various stages of pre-clinical and clinical development, including new over-the-counter eye care products, contact lenses, innovative software and prescription medications for myopia management, next-generation cataract and LASIK surgical equipment, premium intraocular lenses, investigational treatments for dry eye and preservative-free formulations of a range of eye drops. Strong, Experienced Leaders Selected for Board of Directors and Executive Management Team The Bausch + Lomb Board of Directors, which includes the following individuals, has a balance of strong business and health care experience: Joseph C. Papa, Chairman Thomas W. Ross, Sr., Lead Independent Director Nathalie Bernier Richard U. DeSchutter Sarah B. Kavanagh John A. Paulson Russel C. Robertson Andrew C. von Eschenbach, M.D. The Bausch + Lomb executive management team includes: Joseph C. Papa, Chairman and CEO Christina Ackermann, Executive Vice President & General Counsel, and President, Ophthalmic Pharmaceuticals Dennis Asharin, Executive Vice President, Chief Global Manufacturing and Supply Chain Officer Sam Eldessouky, Chief Financial Officer Joseph (Joe) Gordon, President, Global Consumer, Surgical and Vision Care Yehia Hashad, M.D., Executive Vice President of Research & Development and Chief Medical Officer Louis Yu, Ph.D., Executive Vice President, Chief Quality Officer Kelly Webber, Executive Vice President, Chief Human Resources Officer More information, including biographies of the members of the Board of Directors and executive management team and information for investors, can be found on Bausch + Lomb's updated corporate website, Bausch + Lomb Views ESG as Doing Business Well By Doing Good In addition to its commitment to innovation, Bausch + Lomb is dedicated to implementing sustainable business practices and to identifying opportunities to build and enhance our environmental, social and governance initiatives that support all stakeholders, including employees, consumers, eye care professionals and patients. These initiatives include the Bausch Foundation, which contributes financial and product donations to charitable health organizations, as well as the ONE by ONE Recycling program, the first and only contact lens recycling program in the United States, and the Biotrue® Eye Care Recycling program, the first and only eye care recycling program in the United States. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey.


Sector: Healthcare
Industry: Health Care Equipment & Supplies
Keywords: Pharmaceutical Health Care Eyewear Vision Contact Lenses Surgical Equipment Over The Counter Products Lens Care Products Surgical Devices Bausch Health Eye Care Products Myopia

Is BLCO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 20.2
52 Week Low 16.01
Average Volume 2,321,575
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
RSI 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.43
Resistance 3 (R3) 18.50 18.11 18.19
Resistance 2 (R2) 18.11 17.74 18.07 18.11
Resistance 1 (R1) 17.55 17.52 17.36 17.48 18.03
Pivot Point 17.16 17.16 17.06 17.12 17.16
Support 1 (S1) 16.60 16.79 16.41 16.53 15.97
Support 2 (S2) 16.21 16.57 16.17 15.89
Support 3 (S3) 15.65 16.21 15.81
Support 4 (S4) 15.58